Kornimate/medical-research-clean huggingface dataset:
project madd - nih underage dui and ride

Conditions: Underage Drinking; Driving Under the Influence; Drinking, Teen

Summary: project madd was designed to attempt to curb the alarming trends related to drunk driving and to move the field forward by testing a brief parent-intervention's ability to change adolescents' drinking, impaired driving, and riding with impaired driver behaviors. the aim of this project is to provide an easy-to-implement and low-cost alternative parent-based intervention that can be widely disseminated to address this important public health problem.

drunk driving is a major public health problem. the national highway traffic safety administration reported nearly 10,000 people died in alcohol-related crashes in the u.s. in 2014. the problem is further magnified when one considers that each year over 1.3 million drivers in the u.s. are arrested for alcohol-impaired driving. as alarming as these statistics are they pale by comparison to estimates indicating that they only represent 1% of the 121 million self-reported episodes of alcohol-impaired driving among u.s. drivers each year. the proposed research will attempt to curb these alarming trends and move the field forward by conducting a randomized controlled trial testing a brief parent intervention's ability to change adolescents' drinking, impaired driving, and riding with impaired driver behaviors. prior brief parent-based interventions fro this lab have provided sufficient preliminary evidence of participation, communication, and efficacy for changing under-age drinking to warrant a large-scale comprehensive study. the study will use an extremely rigorous design that meets the society for prevention research criteria for efficacy as described in flay et al., a nationally representative sample assessed at 3-waves (baseline, 6 mo. and 12 mo.) to examine generalizability and sustained effects, and an oversampled hispanic/latino subgroup to examine the parent-intervention's potential to reduce a health disparity in an underserved population. the aims are as follows: aim 1: evaluate the efficacy of the parent intervention (short and long term); aim 2: examine mediators of the pbi that directly influence drinking, impaired driving, and riding with impaired driver behaviors; and aim 3: identify moderators to help inform future tailoring and improvement in intervention effectiveness. to the extent that the research is successful, it will provide an easy to implement and low cost alternative that can be widely disseminated to address this important public health problem.

Eligibility criteria:
inclusion criteria: * parent and teen both consent (forming a dyad testing unit); they are part of gfk's knowledgepanel pool of participants exclusion criteria: * outside of the teen age range
improve intervention trial implementing non-invasive circulating tumor dna analysis to optimize the operative and postoperative treatment for patients with colorectal cancer

Conditions: Colorectal Cancer; Circulating Tumor DNA; Adjuvant Chemotherapy; Progression Free Survival

Summary: a open label 1:1 randomized phase ii exploratory study investigating adjuvant therapy in patients with molecular biologically detectable residual disease after primary resection for localized colorectal tumors.

the main clinical hypothesis is that patients having undergone radical resection from crc do not present with detectable tumor dna in the plasma, whereas patients with detectable tumor dna two weeks' post surgery have residual microscopic disease, and consequently a high risk of diseases recurrence which can be prevented with adjuvant chemotherapy. the primary aim of the present study is to investigate - in a randomized trial - if use of standard adjuvant chemotherapy therapy improves the disease free survival in patients with molecular biological residual disease where adjuvant chemotherapy is not standard treatment . secondary aims include investigating molecular biological response to adjuvant chemotherapy in patients with post-operative ctdna.

Eligibility criteria:
inclusion criteria: * surgically removed adenocarcinoma of the colon or rectum * pathologically stage i or ii disease, and radical resection * detectable ctdna in two weeks postoperative plasma sample * no indication for adjuvant chemotherapy according to dccg guidelines (website) * age at least 18 years * ecog performance status 0-2 * clinically eligible for adjuvant chemotherapy at investigators decision. * adequate bone marrow, liver and renal function allowing systemic chemotherapy (absolute neutrophil count ≥1.5x109/l and thrombocytes ≥ 100x109/l. bilirubin ≤ 1.5 x upper normal value and alanine aminotransferase ≤ 3 x upper normal value, and calculated or measured renal glomerular filtration rate at least 30 ml/min) * anticonception for fertile women and for male patients with a fertile partner. intrauterine device, vasectomy of a female subject's male partner or hormonal contraceptive are acceptable • * written and verbally informed consent exclusion criteria: * radiological evidence of distant metastasis, by ct- chest and abdomen * incapacity, frailty, disability and comorbidity to a degree that according to the investigator is not compatible with combination chemotherapy * previous treatment with 5fu or oxaliplatin * neuropathy nci grade \> 1 * other malignant tumor within 5 years except non-melanoma skin cancer or carcinoma in situ cervicis uteri * pregnant (positive pregnancy test) or breast feeding women
dialysis catheter caps case feasibility study

Conditions: Sterile Catheter; Catheter-related Bloodstream Infections; Dialysis Catheter; Dialysis

Summary: the purpose of this research is to evaluate patient comfort and ease of an investigational device called catheter caps case (c3) attached to the hemodialysis catheter over a 15-minute period. you have been asked to take part in this research because you have been identified as a dialysis patient with a hemodialysis catheter.

tunneled hemodialysis catheters are commonly used to administer dialysis to patients with kidney failure to remove excess fluid and waste from the blood. traditionally, the maintenance and protection of these catheters involves the use of gauze and tape to secure the catheter and cover the double lumen and caps. while this method is widely practiced, it has several drawbacks that can affect both patient outcomes and healthcare efficiency. firstly, the use of gauze and tape can be uncomfortable for patients. the adhesive nature of the tape can cause skin irritation and allergic reactions, in addition the gauze can impede visualization of the entire length of the catheter. additionally, the process of routine changing gauze and tape is time-consuming for healthcare providers and can increase the risk of catheter dislodgment during or catheter caps disconnection during removal of tape gauze combination. another significant concern is infection control. gauze and tape do not provide an optimal sterile barrier, which can lead to an increased risk of catheter-related bloodstream infections (crbsis). these infections are associated with prolonged hospital stays, higher hospital healthcare costs, and increased patient mobility and mortality. the catheter caps case was developed to address these issues by providing a more secure and sterile alternative to gauze and tape. the case is designed to cover the catheter's double lumen and end caps, offering added protection and stability. its innovative design aims to reduce the risk of accidental dislodgement, enhance infection control, and improve overall patient comfort by eliminating the need for gauze and adhesive tape.

Eligibility criteria:
inclusion criteria: 1. patients with tunneled dialysis catheter that will not be removed in the next 90 days. 2. patients from the home dialysis program or in-center (outpatient dialysis) patient population. 3. patients who are age 18 years or older exclusion criteria: 1. patient-delayed graft function (dgf) 2. acute kidney injury patients 3. patients with non-tunneled catheter 4. allergies to the biomed elastic 50a resin

Keywords: sterile catheter catheter-related bloodstream infections catheter caps case infection control c3 dialysis catheter caps case dialysis catheter dialysis catheter
role of oral glutathione in skin whitening

Conditions: Skin Whitening

Summary: oral and intravenous glutathione have been used widely to whiten the skin. the investigators tested this hypothesis by giving oral glutathione for 4 weeks to medical students.


Eligibility criteria:
inclusion criteria: * healthy medical students exclusion criteria: * history of skin cancer, especially melanoma * consumption of any preparations containing glutathione within 1 month of enrollment * pigmentary disorders or any dermatoses

Keywords: glutathione melanin whitening uv spots skin pigment
sacral massage with a tennis ball on labor pain and comfort during the intrapartum period

Conditions: Pain Management; Birth Comfort; Massage Effect; Labor Pain

Summary: although pregnancy and labor are physiological events, the pain caused by uterine contractions during labor is among the most severe pains. this causes many women to fear labor. for this reason, control of labor pain should be one of the main goals of the care given to women in labor. therefore, this study was designed to determine the effect of sacral massage with a tennis ball on labor pain and labor comfort in the intrapartum period.

pregnant women hospitalized in the maternity unit will be evaluated for compliance with the inclusion criteria. women who meet the inclusion criteria and are willing to participate in the study will be randomized according to the simple random numbers table and the study group will be determined by the researcher by drawing lots. the purpose and stages of the study will be explained verbally to the women whose group is determined and the women will be asked to read and sign the informed voluntary consent form. then, the pregnancy identification form will be filled in by the researchers using the face-to-face interview method. then the massage will be explained to the pregnant women in the experimental group and they will be asked to evaluate the visual analog scale (vas) before the procedure. while performing this application, the researcher will apply pressure to the sacral region with a tennis ball in a circular motion in a way that the patient can feel but not feel pain. the application will be applied to the pregnant woman for a total of 3 contractions. 30 minutes after each procedure, the woman will be asked to mark the intensity of the pain she feels on the vas scale and to mark the birth comfort scale.

Eligibility criteria:
inclusion criteria: * to be able to read and write turkish, * being over 18 years old * being primiparous * singular foetus and head presentation * pregnancy at term (37-42 weeks) * those without risk factors during pregnancy * being in the active phase of labour in stage 1 * women without any chronic diseases * those without a diagnosed psychiatric illness * to agree to participate in the research exclusion criteria: * if the participant wishes to leave the study voluntarily * administration of any analgesic medication to reduce pain during labour * development of any of the unexpected maternal-fetal risk conditions during labour * having a caesarean section for any reason * the pregnant woman has spine and bone structure problems.

Keywords: sacral massage pain management tennis ball comfort of birth reducing pain labor pain
creation of bone marrow microenvironment for treatment of myelodysplastic syndrome (mds) in conjunction with allogeneic stem cell transplantation

Conditions: Myelodysplastic Syndromes; Myelofibrosis

Summary: normal bone marrow function depends on the coexistence of normal hematopoietic stem cells and a microenvironment mostly located in the medullary part of the bones. stem cells cannot function properly in the absence of an adequate microenvironment. whereas in malignant and non-malignant hematologic diseases caused by a deficiency or abnormal stem cells, stem cell transplantation is the treatment of choice that results in a cure, in diseases such as mds, myelofibrosis, and other conditions associated with an abnormal microenvironment, pancytopenia may occur despite the presence of apparently normal hematopoietic cells with no recognizable cytogenetic abnormality. we, the investigators at hadassah medical organization, proved in experimental studies that the entire osteohematopoietic complex consisting of trabecular bone, hematopoietic microenvironment (of stromal origin) and hematopoietic tissue has been successfully transferred directly into ablated bone marrow cavity in a one-step transplantation procedure. the goal of this study is to enhance hematopoiesis in patients with myelofibrosis syndrome by intraosseous inoculation of demineralized bone matrix (dbm) together with allogeneic bone marrow cells (bmc).


Eligibility criteria:
inclusion criteria: * patients with impaired marrow stem cells by cytogenetic analysis or morphology (blasts), considered normal candidates for allogeneic bmt. such patients will also be entitled to allogeneic bone marrow transplantation with intraosseous dbm. * patients with documented myelofibrosis will be entitled to allogeneic bone marrow transplantation with intraosseous dbm. exclusion criteria: * patients with anticipated life expectancy of \< 4 weeks. * pregnant or lactating women. * patients with an unrelated disease or relevant clinical problem that may not permit evaluation of the results of the study. * patients under 18 years old.

Keywords: myelodysplastic syndrome (mds) allogeneic stem cell transplantation demineralized bone matrix (dbm) bone marrow microenvironment
apatinib with ifosfamide plus etoposide for relapsed or refractory osteosarcoma (oaie)

Conditions: Effect of Drug; Drug; Toxicity

Summary: apatinib has led to positive responses in the treatment of osteosarcoma refractory to first-line chemotherapy. however, apatinib demonstrates only short-lived activity, and the disease control of musculoskeletal lesions is worse than that of pulmonary lesions. this treatment failure has been partly overcome by the addition of ifosfamide and etoposide (ie). we have ever retrospectively compared the activity of apatinib + ie in relapsed or refractory osteosarcoma in two sarcoma centers in china and concluded that for osteosarcoma with multiple sites of metastasis, apatinib + ie demonstrated clinically meaningful antitumor activity and delayed disease progression in patients with recurrent or refractory osteosarcoma after failure of chemotherapy. however to overcome the influence of other interventions on the outcome, we are currently performing a prospective trial to investigate this combination, from which more accurate data on this treatment strategy are expected.


Eligibility criteria:
inclusion criteria: 1. advanced recurrent and refractory osteosarcoma confirmed by histopathology; 2. initial treatment in the orthopedic/oncology departments of peking university people's hospital or peking university shougang hospital; 3. progression less than 6 months after first-line chemotherapy with a combination of high-dose methotrexate, doxorubicin, cisplatin and ifosfamide (first-line chemotherapy); 4. measurable lesions according to the response evaluation criteria for solid tumors (recist 1.1) ; 5. eastern cooperative oncology group performance status ≤ 1 ; 6. acceptable haematologic, hepatic, and renal function. exclusion criteria: 1. those who had been previously treated with antiangiogenic tkis and single ie chemotherapy; 2. those who had severe or uncontrolled medical disorders that could jeopardize the outcomes of the study. these confounding conditions included, cardiac clinical symptoms or disease with left ventricular ejection fraction\<50%, and hypertension that could not be well controlled with antihypertensive drugs.; 3. all patients were assessed by the sarcoma board including a thoracic surgeon with at least 10 years surgical experience. patients with lung metastases only were carefully assessed for eligibility for metastasectomy, of whom those who were suitable for surgery were excluded from this study; 4. weight loss of 20% or more before illness; 5. brain or leptomeningeal metastasis; 6. surgical procedure or radiotherapy within 4 weeks of enrollment; 7. activegastroduodenal ulcer, previous condition associated with risk of bleeding or requiring anticoagulation; 8. proteinuria or hematuria, denutrition with albuminemia \<25 g/l; 9. women who were pregnant or breast feeding, other malignancy; 10. positive hbv/hcv/hiv serology, and known allergy to the experimental agents.

Keywords: osteosarcoma apatinib ifosfamide etoposide
multimodal quantified analysis of facial movements: comparison between pathological and control subjects

Conditions: Electromyography; Eye-tracking; Facial Palsy

Summary: the facial palsy is a frequent disease with a lot of etiologies. it has variable severities with sometimes heavy functional repercussions and different recovery potentials. the proposed treatments are based on surgery, physiotherapy and botulinum toxin injections. however, when recovery is incomplete, acceptance is more difficult, with an impacted quality of life. thanks to motion capture and electromyography, a quantification of the facial mimicry is now possible with a great precision. in addition with the quantification of the facial mimicry, eye-tracking, wich is widely used in the marketing field, but it also finds medical applications including head and neck lesions and facial palsy in particular, will be used to evaluate the visio of the patients on their pathology in function of the movement quantification measured with mocap and electromyography. the aim of this research is to measure in a combined way the action potentials by semg and the amplitudes of displacement of the markers in motion capture, for movements determined in a population of patients presenting a facial pathology, in order to compare them with reference values obtained in healthy subjects. in a second step, the aim will be to study if there is a link between the way the patient looks at his pathology and the results of his management (treatment, rehabilitation) which will be quantitatively evaluated thanks to mocap and semg.


Eligibility criteria:
inclusion criteria: * subjects with no known facial pathology (healthy volunteers) or * patients with peripheral facial palsy, irrespective of grade, whether or not previously treated * subject with written informed consent * subject over 18 years of age * subject affiliated to a social security scheme exclusion criteria: * subjects with severe skin disorders that do not allow the application of electrodes or photo reflective markers * subjects with speech disorders making it impossible to pronounce the sounds \[o\] and \[pu\] * subject unable to provide written informed consent * subjects under guardianship, curators or safeguard of justice

Keywords: facial mimics motion capture electromyography eye-tracking facial palsy
use of recombinant factor vii as a prophylactic therapy for adolescent females with heavy menstrual bleeding

Conditions: Assessing the Bleeding Profile and the Quality of Life of the Enrolled Patients Before and 1 Year After Drug Intervention

Summary: the study is conducted on adolescent females proved to be glanzmanns thrombaesthenia with heavy menstrual bleeding by the use of 3 doses of recombinant factor vii in the first day of their cycles. bleeding profile and quality of life were assessed before and 1year after this regular recombinant factor vii administration.


Eligibility criteria:
inclusion criteria: * adolescent females proved to be glanzmanns thrombaesthenia heavy menstrual bleeding no improvment by platelet transfusion or antifibrinolytic therapy exclusion criteria: chronic systemic disease previous allergic reaction to recombinant fvii -
effect of quadratus lumborum block on perioperative analgesia and inflammatory responses in laparoscopic nephrectomy

Conditions: Postoperative Pain

Summary: quadratus lumborum (ql) block can reduce intraoperative opioid consumption, decrease inflammation responses of il-6, and reduce acute pain intensity in comparison with non-receiving ql block as the control group.

quadratus lumborum block had been studied as an effective postoperative analgesia in lower abdominal surgery, due to its spread to the thoracic paravertebral space and thoracolumbar fascia nerve. the effect of preincisional ultrasound (us)-guided ql block as "preemptive analgesia" on patient underwent laparoscopic living donor nephrectomy has never been evaluated. as preemptive analgesia, quadratus lumborum block could provide analgesics before and after surgery. both groups immediately received basic postoperative analgesia regimen paracetamol 1 gr iv 8th hourly.

Eligibility criteria:
inclusion criteria: * bmi \< 30 kg/m2 * asa 1 or 2 exclusion criteria: * refused to participate * chronic use of analgesics or anti-inflammatory drugs * allergy to local anaesthetic * duration of surgery \ 6 hours * duration of anaesthesia \ 7 hours * neuropathy

Keywords: quadratus lumborum block pre-emptive analgesia laparoscopic nephrectomy
intramuscular peramivir for the treatment of uncomplicated influenza

Conditions: Influenza

Summary: this is a multinational, randomized, double-blind study comparing the efficacy and safety of two single dose regimens of peramivir administered intramuscularly versus placebo in adults with uncomplicated acute influenza.


Eligibility criteria:
inclusion criteria: * male and non-pregnant female subjects age ≥18 years * a rapid antigen test (rat) performed on an adequate specimen collected from an anterior nasal swab. a negative initial rat may be repeated within one hour of obtaining a negative result. * presence of fever at time of screening of ≥38.0 ºc (≥100.4 ºf) taken orally, or ≥38.5 ºc (≥101.2 ºf) taken rectally. for subjects with a positive rat at the time of screening, a subject self-report of a history of fever or feverishness within the 24 hours prior to screening will also qualify for enrollment in the absence of documented fever at time of screening. for subjects with no positive rat at screening, fever as defined above must be documented at time of screening * presence of at least one respiratory symptom (cough, sore throat, or nasal symptoms) of any severity (mild, moderate, or severe) * presence of at least one constitutional symptom (myalgia \[muscle aches\], headache, feverishness, or fatigue) of any severity (mild, moderate, or severe) * onset of symptoms no more than 48 hours before presentation for screening * written informed consent exclusion criteria: * women who are pregnant or breast-feeding * presence of clinically significant signs of acute respiratory distress * history of severe chronic obstructive pulmonary disease (copd) or severe persistent asthma * history of congestive heart failure requiring daily pharmacotherapy with symptoms consistent with new york heart association class iv functional status within the past 12 months * history of chronic renal impairment requiring hemodialysis and/or known or suspected to have moderate or severe renal impairment (actual or estimated creatinine clearance \<50 ml/min) * current clinical evidence of active bacterial infection at any body site that requires therapy with oral or systemic antibiotics * presence of immunocompromised status due to chronic illness, previous organ transplant, or use of immunosuppressive medical therapy * current treatment for active viral hepatitis c * presence of known hiv infection with a cd4 count \<350 cell/mm3 * current therapy with oral warfarin or other systemic anticoagulant * receipt of any doses of rimantadine, amantadine, zanamivir, or oseltamivir in the 7 days prior to screening * immunized against influenza with live attenuated virus vaccine (flumist®) in the previous 21 days * history of alcohol abuse or drug addiction within 1 year prior to admission in the study * participation in a previous study of peramivir as treatment for acute influenza or previous participation in this study * participation in a study of any investigational drug within the last 30 days

Keywords: influenza